Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can dermal fillers reveal the secrets of skin aging?

NCT ID NCT06195605

Knowledge-focused Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This study investigates how skin from adults aged 30-50 responds to injections of a hyaluronic acid filler compared to a saline placebo. Researchers will measure changes in the skin's structural matrix to understand age-related differences. The goal is to learn how fillers interact with aging skin, which could inform future cosmetic treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cross-linked hyaluronic acid dermal filler (Restylane-L) injected into the skin
What this could lead to
If successful, this could reveal how fillers affect skin structure at different ages, potentially guiding personalized cosmetic treatments.
What could go wrong
This is a small, early-stage study with only 15 participants, so results may not apply broadly. Risks include injection-related side effects like swelling or bruising.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects must understand and sign the informed consent prior to participation * Subjects must be in generally good health * Subjects must be able and willing to comply with the requirements of the protocol Exclusion Criteria: * Pregnant, plan to become pregnant during the study, or are nursing a child. Participants will be asked to self-report pregnancy * Individuals with bleeding disorders * Tend to heal poorly or form very thick scars called keloids * Have a lidocaine sensitivity, including those with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction. * Individuals with active inflammation or infection of the skin, including active herpes infection. * Have a significant medical history or concurrent condition which the investigator(s) feel is not safe for study participation, including history of frequent herpes infections, and subjects planning to be exposed to excessive sun, Ultraviolet lamps and extreme cold weather during the first week after injection. * History of allergies to gram positive bacterial proteins * Individuals with who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks. * Have an active inflammation or infection of the skin near the site of injection * Are taking any medications that suppress your immune system * Have severe allergies to medications or other things that we believe might make participation unsafe for you * Have a history of connective tissue diseases, such as: * rheumatoid arthritis * scleroderma * polymyositis/dermatomyositis * systemic lupus erythematosus (SLE)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Photoaging are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Photoaging

Contacts and locations

Locations

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.